Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial
Chieh-Hsin Lin, Ping-Kun Chen, Shi-Heng Wang, Hsien-Yuan Lane, Chieh-Hsin Lin, Ping-Kun Chen, Shi-Heng Wang, Hsien-Yuan Lane
Abstract
Importance: Female gender is a major risk factor for dementia; however, gender has not yet been adequately addressed by clinical trials. A recent study demonstrated that sodium benzoate, a D-amino acid oxidase inhibitor, improved cognitive function in early-phase Alzheimer disease.
Objective: To examine the potential gender difference in the effects of benzoate treatment on the behavioral and psychological symptoms of dementia (BPSD).
Design, setting, and participants: This post hoc secondary analysis used data from a randomized, double-masked, placebo-controlled trial conducted in 3 major medical centers in Taiwan and enrolled 97 patients with BPSD. Data were analyzed between February 2014 and November 2017.
Interventions: Six weeks of treatment of 250 to 1500 mg/d of sodium benzoate or placebo.
Main outcomes and measures: The primary outcome measures were Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) and Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD) scores.
Results: Among 97 total participants (62 [64%] women; mean [SD] age, 75.4 [7.7] years), 49 patients (30 women and 19 men) were randomized to sodium benzoate, and 48 (32 women and 16 men) were randomized to placebo. Among 62 women, 6-week benzoate treatment significantly surpassed placebo in the effects on ADAS-cog performance (mean [SD] difference in score between baseline and end point, -3.1 [6.4] points vs 0 [4.5] points; Cohen d = 0.56; P = .04) but not BEHAVE-AD performance. In contrast, among 35 men, the 2 treatment groups did not differ significantly in both ADAS-cog and BEHAVE-AD scores. Compared with placebo, benzoate treatment also increased estradiol to follicle-stimulating hormone ratios among women (mean [SD] difference between baseline and end point, 0 [0.2] vs -0.1 [0.3]; P = .03).
Conclusions and relevance: These findings suggest that benzoate treatment may improve cognitive function in women with later-phase dementia. In the future, longer dose-finding trials are warranted to further clarify the efficacy of benzoate for later-phase dementia and investigate the role of sex hormones and other factors in the pathogenesis of dementia.
Trial registration: ClinicalTrials.gov Identifier: NCT02103673.
Conflict of interest statement
Conflict of Interest Disclosures: None reported.
References
- Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23. doi:10.1186/s13195-016-0188-8
- Nebel RA, Aggarwal NT, Barnes LL, et al. . Understanding the impact of sex and gender in Alzheimer’s disease: a call to action. Alzheimers Dement. 2018;14(9):1171-1183. doi:10.1016/j.jalz.2018.04.008
- Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer’s disease. Biomed Res Int. 2019;2019:9171424. doi:10.1155/2019/9171424
- Francis PT. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol. 2009;2(1):77-82. doi:10.2174/1874467210902010077
- Lin CH, Lane HY. The role of N-Methyl-D-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia. Front Pharmacol. 2019;10:540. doi:10.3389/fphar.2019.00540
- Lin CH, Huang YJ, Lin CJ, Lane HY, Tsai GE. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease. Curr Pharm Des. 2014;20(32):5169-5179. doi:10.2174/1381612819666140110115603
- Huang YJ, Lin CH, Lane HY, Tsai GE. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Curr Neuropharmacol. 2012;10(3):272-285. doi:10.2174/157015912803217288
- Steinberg M, Shao H, Zandi P, et al. ; Cache County Investigators . Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170-177. doi:10.1002/gps.1858
- Paulsen JS, Salmon DP, Thal LJ, et al. . Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965-1971. doi:10.1212/WNL.54.10.1965
- Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248(3):333-335. doi:10.1001/jama.1982.03330030039022
- Marcoli M, Bonfanti A, Roccatagliata P, et al. . Glutamate efflux from human cerebrocortical slices during ischemia: vesicular-like mode of glutamate release and sensitivity to A(2A) adenosine receptor blockade. Neuropharmacology. 2004;47(6):884-891. doi:10.1016/j.neuropharm.2004.06.022
- Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami E. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A. 2004;101(14):5117-5122. doi:10.1073/pnas.0305741101
- Gusev EI, Skvortsova VI, Dambinova SA, et al. . Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis. 2000;10(1):49-60. doi:10.1159/000016025
- Hsu WY, Lane HY, Lin CH. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. Front Psychiatry. 2018;9:91. doi:10.3389/fpsyt.2018.00091
- Sasabe J, Miyoshi Y, Suzuki M, et al. . D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci U S A. 2012;109(2):627-632. doi:10.1073/pnas.1114639109
- Lin CH, Chen PK, Chang YC, et al. . Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75(9):678-685. doi:10.1016/j.biopsych.2013.08.010
- Van den Berghe-Snorek S, Stankovich MT. Thermodynamic control of D-amino acid oxidase by benzoate binding. J Biol Chem. 1985;260(6):3373-3379. doi:10.1016/S0021-9258(19)83631-1
- Lin CH, Chen PK, Wang SH, Lane HY. Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): a randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol. 2019;33(8):1030-1033. doi:10.1177/0269881119849815
- Hönack D, Löscher W. Sex differences in NMDA receptor mediated responses in rats. Brain Res. 1993;620(1):167-170. doi:10.1016/0006-8993(93)90287-W
- McRoberts JA, Li J, Ennes HS, Mayer EA. Sex-dependent differences in the activity and modulation of N-methyl-d-aspartic acid receptors in rat dorsal root ganglia neurons. Neuroscience. 2007;148(4):1015-1020. doi:10.1016/j.neuroscience.2007.07.006
- Short RA, Bowen RL, O’Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76(9):906-909. doi:10.1016/S0025-6196(11)62109-5
- Kehinde OS, Christianah OI, Oyetunji OA. Ascorbic acid and sodium benzoate synergistically aggravates testicular dysfunction in adult Wistar rats. Int J Physiol Pathophysiol Pharmacol. 2018;10(1):39-46.
- Lin CH, Yang HT, Chen PK, Wang SH, Lane HY. Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD). Neuropsychiatr Dis Treat. 2020;16:509-518. doi:10.2147/NDT.S234371
- Sperling RA, Jack CR Jr, Black SE, et al. . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351
- Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am J Geriatr Psychiatry. 2015;23(2):130-140. doi:10.1016/j.jagp.2013.03.014
- Lane HY, Chang YC, Su MH, Chiu CC, Huang MC, Chang WH. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol. 2002;22(1):4-10. doi:10.1097/00004714-200202000-00002
- Devanand DP, Mintzer J, Schultz SK, et al. . Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497-1507. doi:10.1056/NEJMoa1114058
- Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. doi:10.1001/jama.293.5.596
- Matsuura A, Fujita Y, Iyo M, Hashimoto K. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatr. 2015;27(3):159-167. doi:10.1017/neu.2015.1
- Lane HY, Lin CH, Green MF, et al. . Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12):1267-1275. doi:10.1001/jamapsychiatry.2013.2159
- Lin CH, Lin CH, Chang YC, et al. . Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018;84(6):422-432. doi:10.1016/j.biopsych.2017.12.006
- McCarthny CR, Du X, Wu YC, Hill RA. Investigating the interactive effects of sex steroid hormones and brain-derived neurotrophic factor during adolescence on hippocampal NMDA receptor expression. Int J Endocrinol. 2018;2018:7231915. doi:10.1155/2018/7231915
- Bellanti F, Matteo M, Rollo T, et al. . Sex hormones modulate circulating antioxidant enzymes: impact of estrogen therapy. Redox Biol. 2013;1:340-346. doi:10.1016/j.redox.2013.05.003
- Labhart A. Clinical Endocrinology: Theory and Practice. Springer Science & Business Media; 2015.
- Lemini C, Silva G, Timossi C, et al. . Estrogenic effects of p-hydroxybenzoic acid in CD1 mice. Environ Res. 1997;75(2):130-134. doi:10.1006/enrs.1997.3782
- Routledge EJ, Parker J, Odum J, Ashby J, Sumpter JP. Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic. Toxicol Appl Pharmacol. 1998;153(1):12-19. doi:10.1006/taap.1998.8544
- Harrison PJ. D-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? Biol Psychiatry. 2018;84(6):396-398. doi:10.1016/j.biopsych.2018.06.001
- Steele LS, Glazier RH. Is donepezil effective for treating Alzheimer’s disease? Can Fam Physician. 1999;45:917-919.
- Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. . Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665. doi:10.1136/bmj.l665
- Mallery SR, Zeligs BJ, Ramwell PW, Bellanti JA. Gender-related variations and interaction of human neutrophil cyclooxygenase and oxidative burst metabolites. J Leukoc Biol. 1986;40(2):133-146. doi:10.1002/jlb.40.2.133
- Kumar V, Anand IS, Ganguly NK. Action of oxygen free radical scavengers and inhibitors on the chemiluminescence response of monocytes and neutrophils in rheumatic fever. Cardioscience. 1993;4(3):171-175.
- Kubota K, Ishizaki T. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol. 1991;41(4):363-368. doi:10.1007/BF00314969
- Zu K, Pizzurro DM, Lewandowski TA, Goodman JE. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts. Regul Toxicol Pharmacol. 2017;89:83-94. doi:10.1016/j.yrtph.2017.07.012
- Stanojevic D, Čomić L, Stefanovic O, Solujic S ( Antimicrobial effects of sodium benzoate, sodium nitrite and potassium sorbate and their synergistic action in vitro. Bulgarian Journal of Agricultural Science. 2009;15(4):308-312. Accessed March 19, 2021.
- Chang CH, Lin CH, Lane HY. D-glutamate and gut microbiota in Alzheimer’s disease. Int J Mol Sci. 2020;21(8):2676. doi:10.3390/ijms21082676
- Naveed M, Zhou QG, Xu C, et al. . Gut-brain axis: a matter of concern in neuropsychiatric disorders…! Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110051. doi:10.1016/j.pnpbp.2020.110051
- Lin CY, Liang SY, Chang YC, et al. . Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry. 2017;18(5):357-368. doi:10.3109/15622975.2015.1117654
- Scott JG, Baker A, Lim CCW, et al. . Effect of sodium benzoate vs placebo among individuals with early psychosis: a randomized clinical trial. JAMA Netw Open. 2020;3(11):e2024335. doi:10.1001/jamanetworkopen.2020.24335
Source: PubMed